adtrngm Message Board - Msg: 14339459

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : adtrngm

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: KevRupert who started this subject	9/6/2000 8:38:45 PM
From: KevRupert	of 38

IVAX Legal Info: By Tara Murphy Staff Reporter 9/6/00 7:20 PM ET URL: thestreet.com IVAX(IVX:AMEX) said that a California federal judge rendered a decision that could have the company marketing a generic form of Bristol-Myers Squibb's(BMY:NYSE) cancer treatment Taxol very soon. In August, the Food and Drug Administration gave IVAX tentative approval to sell its drug paclitaxel, providing that IVAX settle a patent dispute that it had with Bristol Myers and BioScience, which holds a patent for the dosage forms of paclitaxel. Judge William Byrne ordered Bristol Myers to register ABI's patent in the FDA's Orange Book, which contains patents for drugs that are already on the market. Usually, an Orange Book listing prevents the FDA from approving generic drug rivals for up to 30 months, allowing patent disputes to be processed in the judicial system. According to an IVAX spokesperson, Judge Byrne threw out his earlier decision, saying that he didn't have jurisdiction over the matter and ordered that the ABI patent be taken out of the Orange Book.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next